MGMT and glioblastoma: To date, the only significant prognostic marker of GBM patient response to TMZ is promoter methylation of the gene encoding for MGMT [5, 6]; specifically, promoter methylation has been identified as a feature of favorable outcome in patients undergoing TMZ therapy for both newly diagnosed GBM and recurrent disease [7].